Glycogen storage disease type III secondary prevention: Difference between revisions
Line 20: | Line 20: | ||
===Cardiology recommendations=== | ===Cardiology recommendations=== | ||
'''Electrocardiogram''' | |||
*Routine ECG should be performed to screen for left ventricular hypertrophy. | |||
'''Echocardiogram'''<ref name="pmid9070576">{{cite journal| author=Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV| title=Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III. | journal=Am J Cardiol | year= 1997 | volume= 79 | issue= 6 | pages= 834-8 | pmid=9070576 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9070576 }} </ref> | |||
* Periodic echocardiogram should be done to measure wall thickness, ventricular mass, systolic function (shortening fraction and ejection fraction), and diastolic function. | |||
* Glycogen storage disease type 3a | |||
** It is recommended to perform serial echocardiogram beginning at the time of diagnosis. | |||
** Repeat every 1–2 year until there is an abnormality by echocardiogram or clinical symptoms suggests poor ventricular function or arrhythmia. | |||
* Glycogen storage disease type 3b | |||
** It is recommended to perform serial echocardiogram beginning at the age of 5 years. | |||
==References== | ==References== |
Revision as of 20:38, 12 December 2017
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III secondary prevention On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III secondary prevention |
FDA on Glycogen storage disease type III secondary prevention |
CDC on Glycogen storage disease type III secondary prevention |
Glycogen storage disease type III secondary prevention in the news |
Blogs on Glycogen storage disease type III secondary prevention |
Risk calculators and risk factors for Glycogen storage disease type III secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- There are no established measures for the secondary prevention of [disease name].
OR
- Effective measures for the secondary prevention of [disease name] include:[1]
- Cardiology recommendations
- [Strategy 2]
- [Strategy 3]
Cardiology recommendations
Electrocardiogram
- Routine ECG should be performed to screen for left ventricular hypertrophy.
Echocardiogram[2]
- Periodic echocardiogram should be done to measure wall thickness, ventricular mass, systolic function (shortening fraction and ejection fraction), and diastolic function.
- Glycogen storage disease type 3a
- It is recommended to perform serial echocardiogram beginning at the time of diagnosis.
- Repeat every 1–2 year until there is an abnormality by echocardiogram or clinical symptoms suggests poor ventricular function or arrhythmia.
- Glycogen storage disease type 3b
- It is recommended to perform serial echocardiogram beginning at the age of 5 years.
References
- ↑ Kishnani, Priya S; Austin, Stephanie L; Arn, Pamela; Bali, Deeksha S; Boney, Anne; Case, Laura E; Chung, Wendy K; Desai, Dev M; El-Gharbawy, Areeg; Haller, Ronald; Smit, G Peter A; Smith, Alastair D; Hobson-Webb, Lisa D; Wechsler, Stephanie Burns; Weinstein, David A; Watson, Michael S (2010). "Glycogen Storage Disease Type III diagnosis and management guidelines". Genetics in Medicine. 12 (7): 446–463. doi:10.1097/GIM.0b013e3181e655b6. ISSN 1098-3600.
- ↑ Lee PJ, Deanfield JE, Burch M, Baig K, McKenna WJ, Leonard JV (1997). "Comparison of the functional significance of left ventricular hypertrophy in hypertrophic cardiomyopathy and glycogenosis type III". Am J Cardiol. 79 (6): 834–8. PMID 9070576.